Our First Target Market is the Treatment of Tinea Pedis and Onychomycosis Conditions
The global tinea pedis treatment market is estimated to reach US$ 1.7 B by 2027 from an estimated market value of around $ 1.0 B in 2017.
The market is growing at a CAGR of 4.8% throughout the period of forecast. (CISION, November 2017)
Current treatment options include topical, OTC creams, sprays and gels.
Leading API prescribed by dermatologists include terbinafine, ciclopirox, clotrimazole among others.
Infectious Skin Disease Market Growth 2018-2025 E
In Millions of USD
Sales of OTC and prescription infectious disease therapies are estimated at more than $8.0 B by 2025.
Topical anti-fungal market within Dermatology specialty markets annualized sales of $ 3.0 B.
Our Path to Commercialization
1. Advance the Pre-IND process of our technology and drugs
2. Transition testing into clinical trials
3. Out-license approved and commercialized products to
an established company, promoted to dermatologists
We are always open to speak to potential investors or partners to accelerate the commercialization of our product and technologies. To speak to us, please contact Mr. Matthew Redling, CEO and Founder at: